IRIS
DE PLACIDO, SABINO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 18.311
NA - Nord America 15.774
EU - Europa 12.589
SA - Sud America 2.169
AF - Africa 475
OC - Oceania 21
Continente sconosciuto - Info sul continente non disponibili 17
Totale 49.356
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 15.114
SG - Singapore 8.309
RU - Federazione Russa 5.787
VN - Vietnam 3.519
CN - Cina 3.253
IT - Italia 2.082
BR - Brasile 1.711
HK - Hong Kong 1.543
DE - Germania 936
FR - Francia 684
NL - Olanda 590
FI - Finlandia 575
UA - Ucraina 525
CA - Canada 381
GB - Regno Unito 362
IN - India 346
IE - Irlanda 323
JP - Giappone 278
SE - Svezia 225
AR - Argentina 182
MX - Messico 168
BD - Bangladesh 146
CI - Costa d'Avorio 144
ZA - Sudafrica 130
KR - Corea 114
IQ - Iraq 107
PL - Polonia 98
PH - Filippine 94
TH - Thailandia 86
PK - Pakistan 72
ID - Indonesia 71
BE - Belgio 70
ES - Italia 69
EC - Ecuador 65
AT - Austria 59
CO - Colombia 52
TR - Turchia 47
VE - Venezuela 46
UZ - Uzbekistan 44
TW - Taiwan 43
MA - Marocco 35
CL - Cile 34
PY - Paraguay 34
CZ - Repubblica Ceca 29
LT - Lituania 28
KE - Kenya 26
TN - Tunisia 26
JO - Giordania 25
EG - Egitto 22
IR - Iran 22
AE - Emirati Arabi Uniti 21
SA - Arabia Saudita 19
NP - Nepal 18
DZ - Algeria 16
DK - Danimarca 15
PE - Perù 15
AZ - Azerbaigian 14
IL - Israele 14
JM - Giamaica 14
MY - Malesia 14
SI - Slovenia 14
UY - Uruguay 14
AU - Australia 13
DO - Repubblica Dominicana 13
KZ - Kazakistan 13
LB - Libano 12
BO - Bolivia 11
ET - Etiopia 11
PS - Palestinian Territory 11
RS - Serbia 11
LV - Lettonia 10
BG - Bulgaria 9
BZ - Belize 9
CR - Costa Rica 9
HN - Honduras 9
NG - Nigeria 9
PT - Portogallo 9
TT - Trinidad e Tobago 9
EU - Europa 8
MD - Moldavia 8
AL - Albania 7
GR - Grecia 7
GT - Guatemala 7
KH - Cambogia 7
MK - Macedonia 7
NI - Nicaragua 7
PA - Panama 7
RO - Romania 7
SY - Repubblica araba siriana 7
GE - Georgia 6
HR - Croazia 6
NZ - Nuova Zelanda 6
PR - Porto Rico 6
SN - Senegal 6
XK - ???statistics.table.value.countryCode.XK??? 6
BH - Bahrain 5
BS - Bahamas 5
BW - Botswana 5
BY - Bielorussia 5
CH - Svizzera 5
Totale 49.227
Salva come PNG Salva come JPEG
Città #
Singapore 3.962
San Jose 2.518
Hong Kong 1.473
Moscow 1.409
Chandler 1.279
Ashburn 1.175
Beijing 1.040
Ho Chi Minh City 985
Hanoi 841
Santa Clara 602
Amsterdam 540
Millbury 509
Jacksonville 502
The Dalles 469
Los Angeles 455
Naples 453
Lauterbourg 424
Hefei 402
Princeton 367
Munich 345
Dallas 281
Napoli 258
Nanjing 254
Tokyo 247
New York 244
Buffalo 218
Wilmington 199
Boston 184
Ottawa 153
Da Nang 151
São Paulo 150
Haiphong 145
Redondo Beach 134
Turku 124
Des Moines 119
Orem 103
Seattle 93
Brooklyn 91
Frankfurt am Main 90
Houston 89
Nanchang 89
Montreal 87
Warsaw 83
London 81
Helsinki 77
Mexico City 77
Chicago 72
Milan 72
Lawrence 67
Nuremberg 67
Rome 67
Tianjin 67
Council Bluffs 66
Dublin 66
Seoul 66
Shenyang 60
Toronto 59
Atlanta 58
Boardman 56
Cagliari 56
Changsha 56
Denver 56
Hebei 56
Johannesburg 56
Pune 56
Brussels 55
Stockholm 55
Chennai 53
Dong Ket 52
Woodbridge 51
San Francisco 50
Biên Hòa 49
Hải Dương 49
Phoenix 49
Rio de Janeiro 46
Baghdad 45
Kochi 45
Washington 44
Jiaxing 42
Norwalk 42
Poplar 42
Falkenstein 41
Can Tho 40
Falls Church 39
Bangkok 38
Tashkent 38
Ninh Bình 37
Kunming 33
Mumbai 33
Manchester 32
Shanghai 32
Belo Horizonte 31
Guayaquil 30
Charlotte 29
Brasília 27
Thái Nguyên 26
Curitiba 24
Kronberg 24
Porto Alegre 24
Long Xuyen 23
Totale 26.120
Salva come PNG Salva come JPEG
Nome #
GIM3-FATA first adjuvant trial on all aromatase inhibitors in early breast cancer. Studio di fase III di coonfronto tra anastrazolo, letrozolo ed exemestane e tra strategia sequenziale (2 anni di terapia con tamoxifene seguiti da tre anni di terapia con inibitori delle aromatasi) verso strategia up-front (5 anni di terapia con inibitori delle aromatasi) nel trattamento adiuvante del carcinoma mammario ormono-responsivo 328
Manuale di Oncologia Clinica 234
Shifting from a Biological-Agnostic Approach to a Molecular-Driven Strategy in Rare Cancers: Ewing Sarcoma Archetype 206
Impaired Seroconversion After Severe Acute Respiratory Syndrome Coronavirus 2 mRNA Vaccine in Patients With Thymic Epithelial Tumors 198
Isoquercetin as an Adjunct Therapy in Patients With Kidney Cancer Receiving First-Line Sunitinib (QUASAR): Results of a Phase I Trial 197
Impact of COVID-19 outbreak on cancer immunotherapy in Italy: A survey of young oncologists 195
Outcomes Associated with First-Line anti-PD-1/ PD-L1 agents vs. Sunitinib in Patients with Sarcomatoid Renal Cell Carcinoma: A Systematic Review and Meta-Analysis 185
Long-term disease control with lapatinib and capecitabine in a patient with HER2-positive metastatic breast cancer pretreated with trastuzumab and trastuzumab-emtansine 183
Prognostic role of sarcopenia in metastatic colorectal cancer patients during first-line chemotherapy: A retrospective study 181
Targeting HER2 as a therapeutic strategy for breast cancer: a paradigmatic shift of drug development in oncology. 179
2D and 3D strain for detection of subclinical anthracycline cardiotoxicity in breast cancer patients: a balance with feasibility 179
A randomised factorial trial of sequential doxorubicin and CMF vs CMF and chemotherapy alone vs chemotherapy followed by goserelin plus tamoxifen as adjuvant treatment of node-positive breast cancer. 178
CDK 4/6 Inhibitors as Single Agent in Advanced Solid Tumors. 178
A specific miRNA signature correlates with complete pathological response to neoadjuvant chemo-radiotherapy in locally advanced rectal cancer 178
FOLFIRI in patients with locally advanced or metastatic pancreatic or biliary tract carcinoma: a monoinstitutional experience 175
Epigenetic silencing of THY1 tracks the acquisition of the Notch1-EGFR signaling in a xenograft model of CD44+/CD24low/CD90+ myoepithelial cells 174
Metabolic and anthropometric changes in early breast cancer patients receiving adjuvant therapy 171
Urotensin II receptor on preoperative biopsy is associated with upstaging and upgrading in prostate cancer 166
Machine Learning and Texture Analysis of [18F]FDG PET/CT Images for the Prediction of Distant Metastases in Non-Small-Cell Lung Cancer Patients 166
Everolimus induces Met inactivation by disrupting the FKBP12/Met complex 165
1599P - Effects of Hedgehog signaling inhibition on epithelial-stromal interactions in triple negative breast cancer cells 162
Discordance in RAS mutations between primary colon tumor and metastases: a real event or a matter of methodology? 162
Prevalence of Sarcopenia in Women with Breast Cancer 161
The impact of schedule on acute toxicity and dose-intensity of high-dose chemotherapy with epirubicin and cyclophosphamide plus colony stimulating factors in advanced breast cancer. 161
A New Horizon of Liquid Biopsy in Thymic Epithelial Tumors: The Potential Utility of Circulating Cell-Free DNA 161
Neoadjuvant Treatment in Locally Advanced Pancreatic Cancer (LAPC) Patients with FOLFIRINOX or Gemcitabine NabPaclitaxel: A Single-Center Experience and a Literature Review. 160
Predictors of efficacy of androgen-receptor-axis-targeted therapies in patients with metastatic castration-sensitive prostate cancer: A systematic review and meta-analysis 160
The Never-Ending History of Octreotide in Thymic Tumors: A Vintage or A Contemporary Drug? 159
Src inhibitors act through different mechanisms in Non-Small Cell Lung Cancer models depending on EGFR and RAS mutational status 159
Fluorouracil and dose-dense adjuvant chemotherapy in patients with early-stage breast cancer (GIM2): end-of-study results from a randomised, phase 3 trial 157
Neuroendocrine differentiation after neoadjuvant hormonal treatment in prostate cancer. 157
Phase II trial of cisplatin plus prednisone in docetaxel-refractory castration-resistant prostate cancer patients 157
Extraskeletal Ewing's sarcoma of the mediastinum: Case report 156
Can high-dose fotemustine reverse MGMT resistance in glioblastoma multiforme? 156
A third-line sorafenib aftrer sequential therapy with sunitinib and mTOR inhibitors in methastatic renal cell carcinoma 155
Concomitant Interferon-alfa and chemotherapy in hepatitis C and colorectal cancer: a case report 155
Addition of erlotinib to fluoropyrimidine-oxaliplatin-basedchemotherapy with or without bevacizumab: Two sequential phase I trials 154
Adjuvant treatment for locally advanced rectal cancer patients after pre-operative chemoradiotherapy: when, and for whom? 154
Combined effect of obesity and diabetes on early breast cancer outcome: A prospective observational study 154
A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer. 153
Toll-like receptor 9 agonist IMO cooperates with everolimus in renal cell carcinoma by interfering with tumour growth and angiogenesis. 153
Strain-oriented strategy for guiding cardioprotection initiation of breast cancer patients experiencing cardiac dysfunction 153
FOLFIRINOX after first-line gemcitabine-based chemotherapy in advanced pancreatic cancer: a retrospective comparison with FOLFOX and FOLFIRI schedules 152
Metabolic syndrome and early stage breast cancer outcome: results from a prospective observational study 152
Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: An open-label, 2 × 2 factorial, randomised phase 3 trial 151
Use of folfirinox or nab-paclitaxel plus gemcitabine for the treatment of locally advanced pancreatic adenocarcinoma: A single institution observational study 151
Optimising triage procedures for patients with cancer needing active anticancer treatment in the COVID-19 era 150
Palbociclib added to ongoing endocrine therapy for hormone receptor-positive HER2-negative metastatic breast cancer: A case report series 150
Risk factors for cancer-related venous thromboembolism in ambulatory patients. 149
Systemic treatment of malignant gastrointestinal neuroectodermal tumour after childhood neuroblastoma: chemotherapy in malignant gastrointestinal neuroectodermal tumour 149
Tumor characteristics and prognosis in familial breast cancer 148
Assessment of Total, PTEN–, and AR-V7+ Circulating Tumor Cell Count by Flow Cytometry in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Enzalutamide 148
Combination of docetaxel and cetuximab for penile cancer: a case report and literature review 147
Role of sphingosine kinase 1 (SphK1) on cetuximab resistance in colorectal cancer models 147
The influence of prednisone on the efficacy of cabazitaxel in men with metastatic castration-resistant prostate cancer 147
Effects of the ErbB1/ErbB2 kinase inhibitor GW2974 on androgen-independent prostate cancer PC-3 cell line growth and NSE, chromogranin A and osteopontin content. 146
Twenty-year results of the Naples GUN randomized trial: predictive factors of adjuvant tamoxifen efficacy in early breast cancer. 145
Pretreatment Serum Concentration of Vitamin D and Breast Cancer Characteristics: A Prospective Observational Mediterranean Study 145
T-DM1 versus pertuzumab, trastuzumab and a taxane as first-line therapy of early-relapsed HER2-positive metastatic breast cancer: an Italian multicenter observational study 145
A phase I study of paclitaxel and epirubicin, without and with filgrastim, for the treatment of platinum-resistant advanced ovarian cancer. 144
Biomarkers in localized prostate cancer 144
The Impact of Translational Research in Breast Cancer Care: Can We Improve the Therapeutic Scenario? 144
Human epidermal growth factor receptor 2 dual blockade with trastuzumab and pertuzumab in real life: Italian clinical practice versus the CLEOPATRA trial results 144
Heterogeneity of glycolytic phenotype determined by 18F-FDG PET/CT using coefficient of variation in patients with advanced non-small cell lung cancer 143
RESULTS OF ADJUVANT TREATMENT IN BREAST CANCER WOMEN AGED MORE THAN 70: ITALIAN COOPERATIVE GROUP EXPERIENCE. 143
Second-line chemotherapy with a hybrid-alternating regimen of bolus 5FU modulated by methotrexate and infusional 5FU modulated by folinic acid in patients with metastatic colorectal cancer pretreated with 5FU. A phase 2 study. 143
. 2009 Apr;20(4):. Activity and toxicity of paclitaxel in pretreated metastatic penile cancer patients. 143
Preventing Venous Thromboembolism in Ambulatory Cancer Patients: The ONKOTEV Study 143
It is no longer the time to disregard thyroid metastases from breast cancer: A case report and review of the literature 143
Docetaxel, vinorelbine, and zoledronic acid as first-line treatment in patients with hormone refractory prostate cancer: a phase II study. 142
A comprehensive outlook on inracerebral therapy of malignant gliomas 142
Modified glasgow prognostic score is associated with risk of recurrence in bladder cancer patients after radical Cystectomy: A multicenter experience 142
A review of the use of next generation sequencing methodologies to identify biomarkers of resistance to CDK4/6 inhibitors in ER+/HER2- breast cancer 142
Taxane-Based Combinations As Adjuvant Chemotherapy of Early Breast Cancer: A Meta-Analysis of Randomized Trials 141
Long-term survival and BRCA status in male breast cancer: A retrospective single-center analysis 141
Fractional microablative CO2 laser for vulvovaginal atrophy in women treated with chemotherapy and/or hormonal therapy for breast cancer: A retrospective study 141
Antitumor activity of combined treatment of human cancer cells with ionizing radiations and anti-epidermal growth factor receptor monoclonal antibody C225 plus type I protein kinase A antisense oligonucleotide. 140
Double complete response in MCRC patient 140
SPHINGOSINE KINASE 1 (SPHK1) CONTRIBUTES TO RESISTANCE TO EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) INHIBITORS IN COLORECTAL CANCER MODELS 140
The dual PI3K/mTOR inhibitor PKI-587 enhances sensitivity to cetuximab in EGFR-resistant human head and neck cancer models. 140
Body weight and risk of molecular breast cancer subtypes among postmenopausal Mediterranean women 140
Inadequate health-related quality of life assessment and reporting in phase III clinical trials of immune checkpoint inhibitors in solid cancers: a systematic review 140
Heterogeneity of SSTR2 expression assessed by 68Ga-DOTATOC PET/CT using coefficient of variation in patients with neuroendocrine tumors 140
P0081 Src inhibitors act through different mechanisms to cooperate with EGFR or MEK inhibitors in NSCLC models sensitive or resistant to erlotinib 139
Management of patients with BRCA1/2-associated breast cancer 139
Mechanisms of lapatinib resistance in HER2-driven breast cancer 139
First-line systemic therapy for metastatic castration-sensitive prostate cancer: An updated systematic review with novel findings 139
Multi-gene panel testing increases germline predisposing mutations' detection in a cohort of breast/ovarian cancer patients from Southern Italy 138
Hedgehog signalling pathway orchestrates angiogenesis in triple-negative breast cancers 137
Management of Germ Cell Tumors During the Outbreak of the Novel Coronavirus Disease-19 Pandemic: A Survey of International Expertise Centers 136
Hypothalamic-pituitary-ovarian axis in women with operable breast cancer treated with adjuvant CMF and tamoxifen. 136
Efficacy of rituximab in gastric diffuse large B cell Lymphoma patients. 136
Androgen receptor in triple negative breast cancer: A potential target for the targetless subtype 136
Insight on the Role of Leptin: A Bridge from Obesity to Breast Cancer 135
Lack of cumulative toxicity associated with cabazitaxel use in prostate cancer 135
Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis 135
Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI) 135
Exploring the interplay between Kaposi's sarcoma and SARS‐CoV‐2 infection: A case series and systematic review 134
The importance of using strain derived criteria for detection of subclinical cardiotoxicity in breast cancer patients undergoing anthracycline and trastuzumab 134
Chemotherapy versus endocrine therapy as first-line treatment in patients with luminal-like HER2-negative metastatic breast cancer: A propensity score analysis 134
Totale 15.519
Salva come PNG Salva come JPEG
Categoria #
all - tutte 158.620
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 158.620
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202182 0 0 0 0 0 0 0 0 0 0 0 82
2021/20222.383 38 8 23 17 44 74 27 97 317 215 560 963
2022/20233.374 470 224 111 227 377 370 31 299 484 540 184 57
2023/20242.306 71 354 359 178 105 229 28 271 35 63 404 209
2024/202513.005 685 788 59 183 326 562 1.217 819 1.141 1.382 4.775 1.068
2025/202624.324 2.735 1.680 2.511 2.234 4.198 1.137 2.854 1.306 3.239 1.652 586 192
Totale 49.981